[ad_1]
Embargoed until 9 a.m. CT / 10 a.m. ET Friday, November 6, 2020
(NewMediaWire) – November 06, 2020 – DALLAS – The American Heart Association (AHA), a global force for longer, healthier lives, will present its 2020 Basic Research Award to Ann Marie Schmidt, M.D., of NYU Grossman School of Medicine for her critical research that has helped us understand the many connections between heart disease and diabetes. She will receive the award during AHA’s Scientific Sessions 2020, which will be held virtually, Friday, November 13 – Tuesday, November 17, 2020, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide.
“This award recognizes the important contributions Dr. Schmidt has made in research, especially the discovery of the receptor for advanced glycation end products, also called RAGE. Her lab, first at Columbia, where we had the chance to collaborate, and now at NYU, has investigated the role of RAGE in the development of cardiometabolic diseases, particularly diabetes, and the way it affects the heart,” said American Heart Association President Mitchell S.V. Elkind, M.D., M.S., FAAN, FAHA. “Her work is integral to our understanding of how inextricably heart disease is intertwined with diabetes, and more recently she has also found links between RAGE and Alzheimer Disease. As a vascular neurologist, I believe this work has already highlighted the links among diabetes, heart disease, and neurodegenerative disease, and has the potential to impact hundreds of millions of lives worldwide.”
Researchers had long suspected that inflammatory and metabolic pathways are tightly coupled; however, what they did not know is that RAGE itself is implicated in the process. Dr. Schmidt’s discovery revealed the possibility of a range of new, targeted treatments for both obesity and one of its key consequences – diabetes and its complications.
Dr. Schmidt founded the Diabetes Research Program at NYU Langone in 2010, along with Ravichandran Ramasamy, Ph.D. This laboratory group studies the biochemical and molecular mechanisms of the complications of diabetes, particularly the links among hyperglycemia, inflammation and diabetic tissue damage.
“Today’s therapeutic approaches—managing weight and blood glucose—are largely aimed at tackling the core manifestations of these disorders, yet these therapies are often not effective and do not address the fundamental cause,” said Dr. Schmidt. Now her team is specifically trying to understand how molecules that increase with obesity and diabetes bind to RAGE and then signal adverse inflammatory and metabolic effects, which suppress energy expenditure—and how to inhibit these effects and release the brakes on optimal use of energy in obesity and in weight loss.
“I greatly hope that in the coming years, the fruits of our collective work on RAGE may deliver a therapeutic for heart disease and metabolic diseases,” said Dr. Schmidt, upon receiving the award. “I sincerely thank you for the recognition of this work and our team’s indefatigable efforts to better the health and lives of humankind.”
Dr. Schmidt has been named a Harrington Scholar-Innovator; a Gabor Kaley Memorial Lecturer for The Microcirculatory Society and the American Physiological Society; and recipient of the 2018 Master Scientist Award, the highest honor bestowed for researchers by New York University Langone Medical Center.
She earned her undergraduate degree and her medical degree with honors from the NYU School of Medicine at New York University. Dr. Schmidt completed internships, her residency and her clinical cardiology training at NYU’s Medical Center, Bellevue Hospital Center. After completing a research fellowship at Columbia University, she taught at Columbia as an associate professor and then professor of the division of surgical science in the department of surgery. In her last role at Columbia, she served as the chief of the division of surgical science in the department of surgery; she returned to NYU in 2010.
Additional Resources:
The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association’s overall financial information is available here.
About the American Heart Association
The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
###
For Media Inquiries:
AHA News Media in Dallas: 214-706-1173; ahacommunications@heart.org
Michelle Kirkwood: 703-457-7838; michelle.kirkwood@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
[ad_2]